Market Overview: The global market for Hematologic Malignancies testing was valued at USD 2.55 Billion in 2021 and is projected to witness a robust revenue CAGR of 14.7% throughout the forecast period. Factors such as increased healthcare investments, growing prevalence of blood cancers like leukemia, lymphoma, and multiple myeloma worldwide, along with heightened awareness among patients and...